- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07560969
Addressing Food Access and Physical Activity to Improve Diabetes Prevention Outcomes Among Underserved African Americans
The goal of this clinical trial is to learn if an enhanced, culturally, socially, and structurally tailored Diabetes Prevention Program (E-DPP) can improve weight loss and related diabetes risk factors in African American adults with prediabetes living in low-income, socially vulnerable communities.
The main questions it aims to answer are:
- Does the enhanced DPP (E-DPP) lead to greater percent weight loss at 6 and 12 months compared to the standard culturally tailored DPP (S-DPP)?
- How do social determinants (e.g., food insecurity, stigma, access to resources) influence weight loss and engagement in lifestyle behaviors?
Researchers will compare a standard culturally tailored DPP (S-DPP) to an enhanced DPP (E-DPP) to see if improving access to healthy food, physical activity, and community resources increases weight loss and improves diabetes-related outcomes.
Participants will
- Attend DPP sessions delivered in community settings (e.g., churches)
- Receive lifestyle education focused on diet, physical activity, and weight loss
- Engage in physical activity (including in-class exercise sessions [E-DPP only] and community-based options)
- Receive support for healthy eating, including food deliveries ([E-DPP only]), food selection guidance, and referrals to food assistance programs
- Receive information and support for accessing community resources for food and physical activity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a cluster-randomized clinical trial designed to evaluate the effectiveness of an enhanced, culturally, socially, and structurally tailored Diabetes Prevention Program (E-DPP) compared to a standard culturally tailored DPP (S-DPP) among African American adults with prediabetes residing in low-income, socially vulnerable communities. The trial will enroll approximately 408 participants across 12 community-based sites (churches), which will be randomized to deliver either S-DPP or E-DPP to minimize contamination across intervention conditions.
Both intervention arms are grounded in the evidence-based DPP lifestyle intervention and incorporate cultural tailoring strategies to improve relevance and acceptability in African American communities. The enhanced intervention builds upon this foundation by explicitly addressing multilevel social determinants that influence engagement in healthy eating and physical activity. Specifically, E-DPP integrates structural supports to improve access to healthy foods and safe, low-cost physical activity opportunities, alongside strategies to address social stigma related to obesity, poverty, and food insecurity.
The E-DPP includes additional components delivered during and between sessions. These include provision of fruits and vegetables during sessions, experiential activities focused on healthy food selection and budgeting, and facilitated linkage to community food resources such as food pantries and assistance programs. Physical activity support includes structured in-session exercise and guidance on accessing community-based physical activity programs. Participants in the E-DPP arm will also receive tailored text messaging designed to reinforce behavior change, promote utilization of community resources, and reduce stigma-related barriers to engagement.
The intervention is delivered over a 12-month period, with assessments conducted at baseline, 6 months, and 12 months. A community-engaged approach informs intervention design and implementation, ensuring alignment with local context and resources. The study is guided by theoretical frameworks that emphasize the role of social and structural determinants in shaping health behaviors and outcomes.
In addition to evaluating intervention effects, the study will examine potential mediators and moderators of weight loss, including social determinant-related stressors, access to resources, and psychosocial factors. A concurrent process evaluation will assess intervention fidelity, dose, participant engagement, acceptability, and feasibility, as well as cost-related considerations. These data will inform identification of key intervention components and support future scalability and dissemination of the enhanced program in underserved communities.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jenifer E Allsworth, PhD
- Phone Number: 816-235-1781
- Email: allsworthj@umkc.edu
Study Contact Backup
- Name: Jannette E Berkley-Patton, PhD
- Phone Number: 816-235-1781
- Email: berkleypattonj@umkc.edu
Study Locations
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- University of Missouri-Kansas City
-
Contact:
- Jenifer E Allsworth, PhD
- Phone Number: 816-235-1781
- Email: allsworthj@umkc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Members of a participating church or user of a participating church's outreach services
- Age 18 years or older
- Prediabetic (score of 5 or higher in the National Diabetes Prevention Program Risk Score or ([body mass index > 24 or history of gestational diabetes] and (5.7-6.4 A1v, 100-125 mg/dL fasting plasma glucose, or 140-149 mg/dL oral glucose tolerance test)
Exclusion Criteria:
- Individuals who are pregnant, breastfeeding or planning to become pregnant in the next year
- Individuals with unsafe blood pressure levels (160 systolic or higher or 100 diastolic or higher) without a medical clearance firn
- Individuals who are not able to engage in low-impact physical activity
- Individuals who do not speak English
- Individuals who live in a household with a participant in this study at a different church
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard Diabetes Prevention Program (S-DPP)
Standard DPP (S-DPP) is a 12-month, in-person lifestyle intervention based on the CDC PreventT2 curriculum, delivered by community peer coaches across 22 sessions (16 core, 6 maintenance).
Coaches conduct pre-program outreach and a pre-session addressing diabetes disparities, goal setting, and attendance barriers.
Each session includes weigh-ins with REDCap capture, review of self-monitoring logs for diet, activity, and goals, and guided delivery of the curriculum.
Participants receive Wi-Fi scales and fitness trackers to support weight loss and physical activity tracking.
Certain sessions provide information on local, low- or no-cost food and physical activity resources to support and maintain behavior change.
|
This intervention adapts the CDC PreventT2 Diabetes Prevention Program into two 12-month delivery models led by community peer coaches with student support across 22 sessions (16 core, 6 maintenance).
Both arms include pre-program outreach, a pre-session addressing diabetes disparities, goal setting and barrier identification, structured sessions with weigh-ins captured in REDCap, review of self-monitoring logs, and guided curriculum delivery.
Participants use Wi-Fi scales and fitness trackers to support behavior change.
The enhanced arm adds tailored text messaging, resource navigation, food access supports, and culturally tailored physical activity to address barriers and improve engagement and sustainability.
|
|
Experimental: Enhanced Diabetes Prevention Program (E-DPP)
Enhanced DPP (E-DPP) is a 12-month intervention based on the CDC PreventT2 curriculum that integrates digital tools, community resources, and culturally tailored supports across 22 sessions (16 core, 6 maintenance).
Coaches conduct pre-program outreach and a pre-session addressing diabetes disparities, goal setting, and attendance barriers.
Sessions include weigh-ins with REDCap capture, review of self-monitoring logs, and guided curriculum delivery.
Participants receive Wi-Fi scales and fitness trackers and access tailored text messages with DPP content and resource links.
Coaches provide additional messaging support.
The model also includes in-class healthy food distribution and culturally tailored physical activity sessions, as well as information on local low- or no-cost resources to support sustained behavior change.
|
This intervention adapts the CDC PreventT2 Diabetes Prevention Program into two 12-month delivery models led by community peer coaches with student support across 22 sessions (16 core, 6 maintenance).
Both arms include pre-program outreach, a pre-session addressing diabetes disparities, goal setting and barrier identification, structured sessions with weigh-ins captured in REDCap, review of self-monitoring logs, and guided curriculum delivery.
Participants use Wi-Fi scales and fitness trackers to support behavior change.
The enhanced arm adds tailored text messaging, resource navigation, food access supports, and culturally tailored physical activity to address barriers and improve engagement and sustainability.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight loss
Time Frame: Baseline, 6 months, 12 months
|
Percent weight loss measured as percent change in weight (in pounds) from baseline at 6 and 12 months
|
Baseline, 6 months, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nutrition security
Time Frame: Baseline, 6 months, 12 months
|
Self-reported nutrition security
|
Baseline, 6 months, 12 months
|
|
Dietary intake
Time Frame: Baseline, 6 months, 12 months
|
Self-reported dietary quality that assesses alignment with US dietary guidelines
|
Baseline, 6 months, 12 months
|
|
DPP Attendance
Time Frame: 6 months
|
Number of DPP sessions attended
|
6 months
|
|
Physical activity (subjective)
Time Frame: Baseline, 6 months, 12 months
|
Self-reported physical activity
|
Baseline, 6 months, 12 months
|
|
Physical activity (objective)
Time Frame: Baseline, 6 months
|
Physical activity measured by accelerometer
|
Baseline, 6 months
|
|
Use of community resources for food access
Time Frame: Baseline, 6 months, 12 months
|
Self-reported use of food access community resources
|
Baseline, 6 months, 12 months
|
|
Use of community resources for physical activity
Time Frame: Baseline, 6 months, 12 months
|
Self-reported use of physical activity community resources
|
Baseline, 6 months, 12 months
|
|
Blood pressure
Time Frame: Baseline, 6 months, 12 months
|
Measured systolic and diastolic blood pressure
|
Baseline, 6 months, 12 months
|
|
Glycosylated hemoglobin
Time Frame: Baseline, 6 months, 12 months
|
Measured A1c categorized via American Diabetes Association guidelines
|
Baseline, 6 months, 12 months
|
|
Food security
Time Frame: Baseline, 6 months, 12 months
|
Self-reported measure of household food security
|
Baseline, 6 months, 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jenifer E Jenifer, PhD, University of Missouri, Kansas City
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Body Weight Changes
- Glucose Metabolism Disorders
- Overweight
- Pathological Conditions, Signs and Symptoms
- Behavior
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Weight Loss
- Diabetes Mellitus
- Motor Activity
Other Study ID Numbers
- 2130354
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)United States
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
DiappyMedSanoiaRecruitingDiabetes Type 1 | Pancreatogenous Diabetes | Diabetes Type 2 on InsulinFrance
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
Clinical Trials on Culturally-tailored, enhanced adaption of Diabetes Prevention Program
-
University of Missouri, Kansas CityChildren's Mercy Hospital Kansas City; University of Massachusetts, Amherst; University... and other collaboratorsRecruitingPreDiabetes | Overweight and ObesityUnited States
-
University of Texas at AustinThe University of Texas Health Science Center, HoustonCompleted
-
Loyola UniversityRecruiting
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)UnknownNovel Model for South Asian Treatment in Diabetes (NaMaSTe-Diabetes) Trial in Primary Care (Namaste)Type 2 Diabetes MellitusCanada
-
Baylor Research InstituteUniversity of North Texas Health Science CenterCompletedObesity | Pre-diabetesUnited States
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); Palo Alto Medical Foundation and other collaboratorsCompletedObesityUnited States
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingPre DiabetesUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)Completed
-
Kaiser PermanenteActive, not recruitingPreDiabetes | Type 2 DiabetesUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAcute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States